Tag: Prescription Drugs
Warfarin, Rivaroxaban Similarly Safe, Effective
Findings among cases of mild atrial fibrillation-related acute ischemic stroke
Adjuvant Nivolumab Tops Ipilimumab in Melanoma
Longer recurrence-free survival for stage IIIB, IIIC, IV melanoma
Mepolizumab Beneficial in COPD With Eosinophilic Phenotype
Lower annual rate of moderate, severe exacerbations for patients receiving 100 mg mepolizumab
Dabrafenib, Trametinib Beneficial in Resected Melanoma
Rate of relapse-free survival up for resected stage III melanoma with BRAF V600E, V600K mutations
Risk of Prematurity, SGA Up for Women on Antiepileptic Drugs
Increased risk for women on AEDs for epilepsy or other indications; risk varies with drug used
Longer Progression-Free Survival for Durvalumab in NSCLC
Longer median progression-free survival from randomization, higher response rate with durvalumab
Median Cost of Cancer Drug Development $648.0 Million
Total revenue from sales of 10 drugs was $67.0 billion, with total R&D spending of $7.2 billion
ASBMR: Romosozumab Reduces Fracture Rate in Osteoporosis
Reduced risk of new vertebral fractures, nonvertebral fractures for romosozumab and alendronate
Alendronate Effective, Safe in ‘Oldest Old’ With Prior Fracture
Alendronate treatment reduced risk of hip fracture with sustained safety
Tiotropium Effective in Mild to Moderate COPD
Daily inhaled dose tied to improvements in FEV1 compared to placebo
